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Abstract: 6-Hydroxy-2-methylbenzofuran-4-carboxylic acid was synthesized in two steps, starting
from 3,5-dihydroxybenzoate. The product was obtained through a direct thermal one-pot cyclization
with propargyl bromide, followed by a base-catalyzed hydrolysis. Its molecular structure was
elucidated by means of mono- and bidimensional NMR techniques, ESI-MS, FT-IR and single-crystal
X-ray diffraction.
Keywords: 6-hydroxy-2-methylbenzofuran-4-carboxylic acid methyl ester; 6-hydroxy-2-
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1. Introduction
Tuberculosis (TB) is a contagious and virulent disease, mainly caused by the pathogen
Mycobacterium tuberculosis (Mtb); despite having afflicted mankind for centuries, it is still responsible
for thousands of deaths in developed and developing countries [1]. The available treatments are
outdated, and their use is characterized by significant drawbacks. The approved regimens require
the administration of four or more drugs for a considerably long time; moreover, the adverse effects
contribute to lowering patient compliance, thus favoring the emergence of drug-resistant Mtb strains [2].
For the past 40 years, the scientific community has been working on two fronts—investigating new
compounds acting on known pathways [3] and exploring several new mycobacterial targets—for the
development of improved therapeutic strategies [4,5]. Furthermore, efforts have been directed towards
the investigation of novel formulations for established drugs, to reduce their side effects and enhance
their biopharmaceutical performances [6]. In the last few years, the still-worrying diffusion of TB
has prompted political forces around the world to step up their commitment to the fight against the
disease, with the organization of the first UN high-level meeting (HLM) on TB, which took place on
26 September 2018 [1].
In recent years, our attention has been turned to the identification of new inhibitors of the salicylate
synthase MbtI, an essential, mycobacterium-specific enzyme involved in iron acquisition [7–10].
In this context, the chromanone nucleus caught our attention: new compounds bearing the chromane
scaffold were synthetized [11], and their biological evaluation allowed the identification of I (Figure 1)
as a novel candidate inhibitor, endowed with a promising activity against MbtI (IC50 = 55 µM).
With the purpose of synthesizing structurally simplified analogs of compound I that were devoid
of the carbonyl function at position 4 and of the methyl group in 2, we unexpectedly isolated a new
benzofuran derivative (1), which was submitted to a complete chemical characterization and tested
against MbtI.
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Figure 1. 7-Hydroxy-2-methyl-4-oxo-3,4-dihydro-2H-benzopyran-5-carboxylic acid (I). 
With the purpose of synthesizing structurally simplified analogs of compound I that were 
devoid of the carbonyl function at position 4 and of the methyl group in 2, we unexpectedly isolated 
a new benzofuran derivative (1), which was submitted to a complete chemical characterization and 
tested against MbtI. 
2. Results and Discussion 
6-Hydroxy-2-methylbenzofuran-4-carboxylic acid (1) was synthesized by a two-step reaction 
(Scheme 1). The commercially available methyl 3,5-dihydroxybenzoate was reacted with propargyl 
bromide, copper iodide, potassium iodide and potassium carbonate, through a direct thermal 
intramolecular cyclization. Under these conditions, the phenyl propargyl ether gave a Claisen 
rearrangement [12,13], ultimately leading to the formation of the 2-methylbenzofuran derivative, 
which was then hydrolyzed to the corresponding acid under basic conditions. 
 
Scheme 1. Synthesis of 6-hydroxy-2-methylbenzofuran-4-carboxylic acid (1). 
Compounds 1 and 2 were characterized by means of various spectroscopic and spectrometric 
methods, including mono- and bidimensional NMR, FT-IR and ESI-MS. The structure elucidation of 
compound 2 was supported by a COSY experiment, which evidenced a correlation between the 
methyl group at position 2 and the hydrogen in 3. Furthermore, the NOESY spectrum showed a 
correlation between the hydroxyl function and hydrogens 5–7, and between the methyl of COOCH3 
and hydrogens 3–5. 
Single-crystal X-ray diffraction was employed to determine the molecular structure of 1; its 
ORTEP [14] representation is reported in Figure 2. The compound crystallized in the triclinic P-1 
space group: the asymmetric unit (ASU) accommodates one molecule, with the alcoholic hydrogen 
split over two positions with a 0.5 occupancy. 
 
Figure 2. ORTEP plot of 1, with the arbitrary atom numbering (ellipsoids are at 40% probability and 
H atoms are represented as spheres of arbitrary radii). 
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2. Results and Discussion
6-Hydroxy-2-methylbenzofuran-4-carboxylic acid (1) was synthesized by a two-step reaction
(Scheme 1). The commercially available methyl 3,5-dihydroxybenzoate was reacted with propargyl
bromide, copper iodide, potassium iodide and potassium carbonate, through a direct thermal
intramolecular cyclization. Under these conditions, the phenyl propargyl ether gave a Claisen
rearrangement [12,13], ultimately leading to the formation of the 2-methylbenzofuran derivative,
which was then hydrolyzed to the corresponding acid under basic conditions.
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Sche e 1. Synthesis of 6-hydroxy-2- ethylbenzofuran-4-carboxylic acid (1).
Compounds 1 and 2 were characterized by means of various spectroscopic and spectrometric
methods, including mono- and bidimensional NMR, FT-IR and ESI-MS. The structure elucidation
of compound 2 was supported by a COSY experiment, which evidenced a correlation between the
methyl group at position 2 and the hydrogen in 3. Furthermore, the NOESY spectrum showed a
correlation between the hydroxyl function and hydrogens 5–7, and between the methyl of COOCH3
and hydrogens 3–5.
Single-crystal X-ray diffraction was employed to determine the molecular structure of 1; its
ORTEP [14] representation is reported in Figure 2. The compound crystallized in the triclinic P-1 space
group: the asymmetric unit (ASU) accommodates one molecule, with the alcoholic hydrogen split over
two positions with a 0.5 occupancy.
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Figure 2. ORTEP plot of 1, with the arbitrary atom numbering (ellipsoids are at 40% probability and H
atoms are represented as spheres of arbitrary radii).
The arrangement of the hydroxyl group can be explained by examining the crystal packing, which
shows chains of dimers developing along the c axis (Figure 3). Such dimers are interconnected by a
H-bond, formed between O4 and the hydroxyl hydrogen of two adjacent molecules. This linkage
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justifies the double orientation of the OH; in the donor molecule, the hydrogen (H42) points outward,
towards the next dimer, while in the acceptor molecule, the hydrogen (H41) turns inward, towards the
other monomer. The two monomers, related by a point of inversion, interact through two equivalent
H-bonds, established between the hydrogen and the oxygen of the carboxylic moieties. The aromatic
nature of the compound confers rigidity and planarity to the structure. As a consequence, the packing
is further stabilized by parallel-displaced pi–pi stacking interactions between the heteroaromatic rings,
along the a axis. These stacked chains are 3.875(1) Å apart, as calculated from the ring centroids.
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A summary of the H nds established within the crystal structure is reported in Table 1, along
with a complete account of their geometry, as calculated by PARST [15].
Table 1. Hydrogen-bond geometry of 1 (arbitrary atom-numbering scheme used in Figure 2).
H-Bond H···A (Å) D···A (Å) D-H···A (◦)
O3-H3···O2 1.82(1) 2.623(1) 167.8(1)
O4-H42···O4 1.95(1) 2.745(1) 165.4(1)
The activity of the synthesized compounds was tested against the recombinant MbtI, as previously
reported [9]. As expected from our previous data, the ester (2) showed a poor activity (% residual
enzymatic activity at 100 µM: 82.5 ± 11.1), while the free acid (1) exhibited a promising inhibitory effect
(% residual enzymatic activity at 100 µM: 34.5 ± 10.1). Hence, the IC50 value of 1 was calculated to be
51.9 ± 10.1 µM, revealing a comparable activity to that of our previous chromane-based lead, I.
3. Materials and Methods
3.1. Sy thesis
All reagents and solvents were purchased from Sigma-Aldrich (St. Louis, MO, USA). All the
reactions involving air-sensitive reagents were carried out using anhydrous solvents, in oven-dried
glassware and under nitrogen atmosphere. Melting points were recorded on a Buchi M-565 apparatus
(Buchi, Flawil, Switzerland), and are uncorrected.
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NMR spectra were recorded at room temperature either on a Varian Mercury (Varian, Palo Alto,
CA, USA), equipped with an Oxford 300 MHz cryomagnet (Oxford Instruments, Abingdon, UK),
operating at 300 MHz for 1H analyses, or on a Bruker Avance 500 (Bruker, Billerica, MA, USA),
operating at 500 MHz. DMSO-d6 was used as deuterated solvent for all acquisitions. Chemicals shifts
are expressed in ppm (δ) from tetramethylsilane resonance in the indicated solvent; coupling constants
(J-values) are given in Hertz (Hz). 1H data are reported in the following order: ppm, multiplicity
(s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet), number of protons and attribution. The APT
sequence was used to distinguish methyl and methine signals from those due to methylene and
quaternary carbons.
For FT-IR analyses, compounds were mixed in 1:100 w/w ratio with KBr and pressed through a
hydraulic press (14 tons) to small tablets; data were recorded on a PerkinElmer SPECTRUM ONE
instrument (PerkinElmer, Waltham, MA, USA), in the region between 4000 and 450 cm−1, performing
8 scans at 4 cm−1 resolution.
Mass Spectrometry analyses were carried out on a Thermo Finnigan LCQ Advantage (Thermo
Fisher Scientific, Waltham, MA, USA), equipped with an ESI electrospray ionization source and an Ion
Trap mass analyzer; ionization: ESI positive or ESI negative; capillary temperature: 250 ◦C; source
voltage: 5.50 kV; source current: 4.00 µA; multipole 1 and 2 offset: −5.50 V and −7.50 V, respectively;
intermultipole lens voltage: −16.00 V; trap DC offset voltage: −10.00 V.
NMR, FT-IR, and MS spectra of the synthesized compounds are provided in the
Supplementary Materials.
3.1.1. 6-Hydroxy-2-methylbenzofuran-4-carboxylic Acid Methyl Ester (2)
Propargyl bromide (0.43 mL, 4.76 mmol), anhydrous K2CO3 (1.65 g. 11.90 mmol), KI (1.68 g,
10.12 mmol) and CuI (0.03 g, 0.18 mmol) were added under nitrogen atmosphere to a solution of
3,5-dihydroxybenzoate (1.00 g, 5.95 mmol) in dry DMF (4 mL), and the mixture was heated at 75 ◦C
for 24 h. The residue obtained by the evaporation in vacuum of DMF was poured in ice-water and
then extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over Na2SO4
and evaporated under reduced pressure; the crude residue was purified by column chromatography
(silica gel ratio 1:60), using hexane/ethyl acetate (8:2 to 7:3), to afford compound 2 as a pale yellow
solid (yield: 47%). Rf = 0.32 (hexane/EtOAc 8:2). M.p.: 140–142 ◦C. 1H-NMR (300 MHz, DMSO): δ 9.75
(s exch D2O, 1H, OH), 7.33 (d, J = 2.2 Hz, 1H, H5), 7.14 (dd, J = 2.2, 0.9 Hz, 1H, H7), 6.86–6.80 (m, 1H,
H3), 3.88 (s, 3H, COOCH3), 2.42 (s, 3H, CH3) ppm. 13C-NMR (75 MHz, DMSO): δ 187.61, 166.86, 156.64,
156.46, 154.87, 122.31, 121.68, 113.64, 104.10, 103.41, 52.79, 14.51 ppm. FT-IR (KBr): ν 3405, 3091, 2957,
2919, 2849, 1697, 1623, 1605, 1513, 1441, 1424, 1127, 999 cm−1. ESI-MS (m/z): calcd. for C11H10O4 206,06,
found 205.12 m/z [M − H]−.
3.1.2. 6-Hydroxy-2-methylbenzofuran-4-carboxylic Acid (1)
A solution of powdered NaOH (30 mg, 0.75 mmol) in water (1 mL) and methanol (0.4 mL) was
added to compound 2 (70 mg, 0.34 mmol). The reaction mixture was stirred at 55 ◦C for 6 h and then
partially concentrated in vacuum to remove methanol. The pH of the solution was adjusted to pH 3–4
by the addition of a few drops of 1 M HCl, thereby inducing the precipitation of the free acid 1, which
was collected by filtration as a white solid (yield: 50%). Rf = 0.1 (EtOAc/MeOH 8:2). M.p.: 208–210 ◦C.
1H-NMR (300 MHz, DMSO): δ 12.88 (s exch D2O, 1H, COOH), 9.67 (s exch D2O, 1H, OH), 7.28 (d,
J = 2.2 Hz, 1H, H5), 7.07 (d, J = 2.2, Hz, 1H, H7), 6.80 (s, 1H, H3), 2.39 (s, 3H, CH3) ppm. 13C-NMR
(75 MHz, DMSO): δ 167.59, 156.04, 155.81, 154.38, 122.57, 122.07, 113.49, 103.88, 102.52, 14.08 ppm.
FT-IR (KBr): ν 3281, 3077, 2962, 2919, 2848,1690, 1626, 1600, 1496, 1439, 1392, 1127 cm−1. ESI-MS (m/z):
calcd. for C10H8O4 192.17, found 191.41 m/z [M − H]−.
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3.2. Single-Crystal X-ray Diffraction
The slow evaporation of a methanol/water 1:1 solution of 1 afforded diffraction-quality yellow
laminar crystals, after about one week at room temperature.
Crystallographic data for 1 were collected at ambient temperature on a Bruker-Axs CCD-based
three-circle diffractometer, using graphite-monochromatized Mo-Ka X-radiation (λ = 0.7107 Å).
X-ray diffraction data in the θ range 2◦–25◦ were collected by acquiring four sets of 600
bidimensional CCD frames with the following operative conditions: omega rotation axis; scan width:
0.3◦; acquisition time: 20 s; sample-to-detector distance: 60 mm; ϕ angle: fixed at four different values
(0◦, 90◦, 180◦, 270◦) for the four different sets. Omega-rotation frames were processed with SAINT [16]
for data reduction (including intensity integration, background, Lorentz and polarization corrections)
and for the determination of accurate unit-cell dimensions, obtained by least-squares refinement of the
positions of 1359 independent reflections with I > 10σ(I) in the θ range 2◦–24◦. Absorption effects were
empirically evaluated with the SADABS software [17], and absorption correction was applied to the
data (0.874 and 0.994 as min and max transmission factor, respectively).
The structures were solved by direct methods using SIR-14 [18] and completed by iterative
cycles of full-matrix least-squares refinement on F02 and DF synthesis using SHELXL-17 [19] on the
WingX.v2014.1 suite [20]. Hydrogen atoms bonded to carbons were included at geometrically calculated
positions and refined using a riding model. The contribution of disordered solvent molecules, embedded
in the crystal, to the calculated structure factors was determined with PLATON SQUEEZE [21],
and included in the final steps of the refinement. Graphical representations were rendered with
Mercury 4.3.1 [22]. CCDC entry 2004172 contains the supplementary crystallographic data for this
paper. These data can be obtained free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html
(or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: +44 1223 336033; E-mail:
deposit@ccdc.cam.ac.uk).
Crystal data for compound 1: C10H8O4, Mr = 192.16 g/mol, Triclinic, Space group P-1, a = 3.7850(6)
Å, b = 10.1380(16) Å, c = 14.416(2) Å, α = 104.780(2)◦, β = 94.920(2)◦, γ = 100.720(2)◦, V = 520.35(14)
Å3, Z = 2, Dcalc = 1.226 Mg/m3, F(000) = 200, R = 0.057 for 1383 reflections with Fo > 4sig(Fo)
(R = 0.073 for all 1842 unique/4979 collected reflections), wR2 = 0.172 for reflections with Fo > 4sig(Fo)
(wR2 = 0.186 for all unique reflections), T = 293(2) K, GOF = 1.084. The reflections were collected in
the range 1.475◦ ≤ θ ≤ 25.043◦ (limiting indices = −4 ≤ h ≤ 4, −12 ≤ k ≤ 12, −17 ≤ l ≤ 17) employing a
0.26 × 0.15 × 0.06 mm crystal. The residual positive and negative electron densities in the final map were
0.214 and −0.133 Å−3.
3.3. Enzymatic Assays
Recombinant M. tuberculosis MbtI was produced and purified as previously reported [8,9]. Enzyme
activity was determined by measuring the production of salicylic acid through a fluorimetric assay,
slightly modified from Vasan et al. [23]. The tests were performed at 37 ◦C in a final volume of 400 µL
of 50 mM Hepes pH 7.5, 5 mM MgCl2, using 1–2 µM MbtI; the reactions were started by the addition of
chorismic acid and monitored using a PerkinElmer LS3 fluorimeter (Ex. λ = 305 nm, Em. λ = 420 nm).
Residual enzymatic activity was calculated in the presence of the compound at 100 µM (stock solution
20 mM in DMSO) and 50 µM chorismic acid. IC50 was determined by measuring enzyme activity at
different compound concentrations, and fitting data to the equation:
A[I] = A[0] ×
(
1− [I]
[I] + IC50
)
where A[I] is the activity of the enzyme at inhibitor concentration [I] and A[0] is the activity of the
enzyme without inhibitor.
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Supplementary Materials: The following are available online: http://www.mdpi.com/1422-8599/2020/2/M1143/s1
Figure S1: 1H-NMR spectrum of 6-hydroxy-2-methylbenzofuran-4-carboxylic acid methyl ester (2), Figure S2:
13C-NMR spectrum of methyl ester (2), Figure S3: COSY spectrum of methyl ester (2), Figure S4: NOESY spectrum
of methyl ester (2), Figure S5: HSQC spectrum of methyl ester (2), Figure S6: HMBC spectrum of methyl ester (2),
Figure S7: FT-IR spectrum of methyl ester (2), Figure S8: ESI-MS spectrum of methyl ester (2), Figure S9: 1H-NMR
spectrum of 6-hydroxy-2-methylbenzofuran-4-carboxylic acid (1), Figure S10: 13C-NMR spectrum of acid (1),
Figure S11: FT-IR spectrum of acid (1), Figure S12: ESI-MS spectrum of acid (1).
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